• Molecular NameReboxetine
  • Synonymreboxetine; Reboxetine mesylate
  • Weight313.397
  • Drugbank_IDDB00234
  • ACS_NO98769-81-4
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)3.13
  • pkaN/A
  • LogD (pH=7, predicted)2.36
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-1.58
  • LogSw (predicted, AB/LogsW2.0)0.16
  • Sw (mg/ml) (predicted, ACD/Labs)0.35
  • No.of HBond Donors1
  • No.of HBond Acceptors4
  • No.of Rotatable Bonds6
  • TPSA39.72
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn antidepressant drug used in the treatment of clinical depression, panic disorder and ADD/ADHD
  • Absorption_valueN/A
  • Absorption (description)Reboxetine is rapidly and extensively absorbed following oral administration.
  • Caco_2N/A
  • Bioavailability94.0
  • Protein binding97.0
  • Volume of distribution (VD)32 L; steady state, 0.39 L/kg (R,R)-(??)-reboxetine; 0.92 L/kg (S,S)-(+)-reboxetine.
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmReboxetine is metabolized by dealkylation, hydroxylation and oxidation followed by glucuronide or sulphate conjugation. It is metabolized by the cytochrome P450 CYP isoenzyme 3A4.
  • Half life13~15 h
  • ExcretionRenal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityReports of seizures (rare) have been reported
  • LD50 (rat)N/A
  • LD50 (mouse)N/A